MIRA PHARMACEUTICALS INC (MIRA) Stock News

USA - Nasdaq - NASDAQ:MIRA - US60458C1045 - Common Stock

1.46 USD

+0.06 (+4.29%)

Last: 12/2/2025, 1:03:32 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MIRA Latest News, Press Relases and Analysis

All

Press Releases

22 days ago - By: Benzinga - Mentions: SGMO NNVC REVB CYCN ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: ACCESS Newswire

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

2 months ago - By: Stocktwits

News Image

Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making

3 months ago - By: ACCESS Newswire

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

2 months ago - By: Benzinga

MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data

2 months ago - By: ACCESS Newswire

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

2 months ago - By: ACCESS Newswire

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

2 months ago - By: ACCESS Newswire

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

3 months ago - By: ACCESS Newswire

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

4 months ago - By: ACCESS Newswire

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

4 months ago - By: ACCESS Newswire

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

4 months ago - By: ACCESS Newswire

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

4 months ago - By: ACCESS Newswire

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

5 months ago - By: ACCESS Newswire

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

5 months ago - By: ACCESS Newswire

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

5 months ago - By: ACCESS Newswire

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition